Glucan polyethylene glycol cross-linked polymer microparticle solution as well as preparation method and application thereof

Abstract

The invention discloses a glucan polyethylene glycol cross-linked polymer microparticle solution as well as a preparation method and application thereof. The glucan polyethylene glycol cross-linked body microparticle contains two repetitive structural units: a first structural unit and a second structural unit, the first structural unit is from a first monomer, and the first monomer is polyethylene glycol diacrylate and has a structure A; the second structural unit is from a second monomer, and the second monomer is modified macromolecular glucan and has a structure B; the glucan polyethylene glycol cross-linked body microparticle solution is formed by performing ultraviolet cross-linking on a first monomer and a second monomer. The dextran polyethylene glycol cross-linked body microparticle solution can be used for preparing medical beauty products. After the skin care product is used, subcutaneous autologous regenerated collagen filling and wrinkle removal are realized, the appearance is natural, and the maintenance time is long. The dextran polyethylene glycol cross-linked microparticle solution is simple in preparation procedure and high in product yield.

Description

Technical Field

[0001] The invention belongs to the field of biomedical technology, and relates to autologous regenerative medical technology, in particular to a dextran polyethylene glycol cross-linked microparticle solution, and a preparation method and application thereof. Background Art

[0002] Injection beauty is a non-surgical cosmetic method with a wide range of applications. Biomaterials or synthetic materials with good biocompatibility are injected into the dermis or subcutaneous layer to reduce skin wrinkles or plasticity through local filling or other different mechanisms of action.

[0003] There are two main types of filling products on the market. One is hyaluronic acid (hyaluronic acid) and collagen intradermal or subcutaneous filling, which is an exogenous filling material with disadvantages such as unnatural appearance, easy decomposition, and short maintenance time. The other is PLLA baby face injection, which stimulates the production of autologous collagen to produce a natural filling effect, but is difficult to make and must be freeze-dried powder. The particles must be strictly controlled at 40-63 microns. Particles smaller than 30 microns will be phagocytosed by macrophages to form granulomas, affecting the cosmetic effect.

[0004] Therefore, there is a need for a beauty product that has a natural appearance, is not easily decomposed, lasts for a long time, and has low manufacturing requirements. Summary of the invention

[0005] The purpose of the present invention is to provide a dextran polyethylene glycol cross-linked microparticle solution and its preparation method and application. After using the present invention, through the characterization of the proliferating macrophage M2 in the dermis, the proliferation of collagen, elastin, fibronectin and hyaluronic acid is promoted at the same time, the subcutaneous support is improved, the appearance is natural and the maintenance time is long; the dextran polyethylene glycol cross-linked microparticle solution is used to make medical beauty products, the production technology is stable, and the yield is high.

[0006] The technical solution of the present invention is a dextran polyethylene glycol crosslinked body (Dex-AE / PEGDA) microparticle solution, which contains two repeating structural units: a first structural unit and a second structural unit, wherein the first structural unit is derived from a first monomer, which is polyethylene glycol diacrylate (PEGDA) and has structure A; and the second structural unit is derived from a second monomer, which is a modified high molecular weight dextran (Dex-AE) and has structure B.

[0007]

[0008] Wherein m=10-100, n=4-400, R1 is selected from -OCNHCH2CH=CH2, -CH2CH2NH2 or H; R2 is selected from -OCNHCH2CH=CH2, -CH2CH2NH2 or H; R3 is selected from -OCNHCH2CH=CH2, -CH2CH2NH2 or H; the dextran polyethylene glycol cross-linked microparticle solution is formed by ultraviolet cross-linking of the first monomer and the second monomer. The dextran polyethylene glycol cross-linked microparticle is a bioactive material with high biocompatibility and no irritation. The lumps at the site of use can disappear and recover after 6-8 hours. The dextran polyethylene glycol cross-linked microparticle is decomposed into glucose and PEG by dextranase in the body. PEG is a drug preparation certified by FDA and NMPA. It has the characteristics of non-toxicity, non-immunogenicity, non-antigenicity, water solubility, and can be excreted through the kidneys. The dextran polyethylene glycol cross-linked microparticle solution is injected subcutaneously to promote the proliferation of macrophages in the subcutaneous tissue of the corresponding part, and more than 90% of the proliferating macrophages are characterized by M2. M2 macrophages promote the proliferation of fibroblasts and blood vessel endothelial cells by secreting TGF-β, IL-10, VEGF-A and growth factors. Fibroblasts synthesize and secrete extracellular matrix (EMC) and collagen (type I, type III), elastin and fibronectin; EMC is a matrix composed of macromolecules and minerals, including collagen, enzymes, hyaluronic acid, glycoproteins, proteoglycans, glycosaminoglycans and hydroxyapatite, forming collagen fibers, reticular fibers and elastic fibers, providing structural and biochemical support for surrounding cells, providing support for remodeling the dermal tissue structure, and eliminating wrinkles and defects in the epidermis. Because it is a fiber filling formed by autologous regenerated collagen, it has a very natural appearance effect, and the filling effect can be maintained for 18-24 months.

[0009] In the aforementioned dextran-polyethylene glycol cross-linked microparticle solution, the dextran-polyethylene glycol cross-linked microparticle has structure C,

[0010]

[0011] The average molecular weight of structure A is 200-20,000 Daltons, and the average molecular weight of structure B is 20,000-200,000 Daltons.

[0012] In the aforementioned dextran-polyethylene glycol cross-linked microparticle solution, the average molecular weight of the structure A is 1000-8000 Daltons, and the average molecular weight of the structure B is 10,000-150,000 Daltons.

[0013] In the aforementioned dextran-polyethylene glycol cross-linked microparticle solution, the particle length of the dextran-polyethylene glycol cross-linked microparticle is 10-40 μm. The filling effect of the dextran-polyethylene glycol cross-linked microparticle with this particle length can be maintained for up to 24 months.

[0014] The method for preparing the above-mentioned dextran polyethylene glycol cross-linked microparticle solution is to add a photoinitiator and purified water to the first monomer and the second monomer, and then perform ultraviolet cross-linking to obtain a dextran polyethylene glycol cross-linked microparticle solution. The dextran polyethylene glycol cross-linked microparticles obtained by the method are strip-shaped fibers with a fiber length of 10-40 μm, and the solution is transparent golden yellow, slightly viscous, and has a pH of 7.2-7.4.

[0015] The method for preparing the above-mentioned dextran polyethylene glycol cross-linked microparticle solution comprises the following steps:

[0016] Step A, preparing a solution according to the following concentrations: 80-90 wt % of PBS buffer, 1-4 wt % of a first monomer polyethylene glycol diacrylate aqueous solution, and 8-18 wt % of a second monomer modified high molecular weight dextran aqueous solution;

[0017] Step B, weighing the photoinitiator I2959 according to 3-8% of the total weight of the first monomer and the second monomer;

[0018] Step C, mixing the first monomer aqueous solution, the second monomer aqueous solution, the PBS buffer solution, and I2959, wherein the weight ratio of the first monomer: the second monomer: the PBS is (1-4): (8-18): (80-90), stirring evenly, filtering twice through a 0.5 μm precision filter pump, and injecting into a syringe;

[0019] Step D, placing the filled syringe flat under a 365nm ultraviolet light source, and performing cross-linking reaction at 20-25°C for 10-12h to obtain a dextran polyethylene glycol cross-linked microparticle solution.

[0020] In the aforementioned method for preparing the dextran-polyethylene glycol cross-linked microparticle solution, in step C, the weight ratio of the first monomer: the second monomer: PBS is 1:9:90.

[0021] In the aforementioned method for preparing the dextran-polyethylene glycol cross-linked microparticle solution, in step C, the weight ratio of the first monomer: the second monomer: PBS is 2:8:90.

[0022] In the aforementioned method for preparing the dextran-polyethylene glycol cross-linked microparticle solution, in step C, the weight ratio of the first monomer: the second monomer: PBS is 2:18:80.

[0023] In the aforementioned method for preparing the dextran-polyethylene glycol cross-linked microparticle solution, in step C, the weight ratio of the first monomer: the second monomer: PBS is 4:16:80.

[0024] Application of the aforementioned dextran-polyethylene glycol cross-linked microparticle solution in the preparation of medical cosmetic products.

[0025] The aforementioned dextran polyethylene glycol cross-linked microparticle solution is used in the preparation of medical cosmetic products. The dextran polyethylene glycol cross-linked microparticle solution is used as the main material, and one or more acceptable auxiliary materials are added to prepare the medical cosmetic products.

[0026] The aforementioned dextran polyethylene glycol cross-linked microparticle solution is used in the preparation of medical cosmetic products, and the medical cosmetic products are products for forming subcutaneous support, promoting deep skin (deep to the dermis or below, clinically referred to as deep skin) wound healing products, or surface surgical site repair products. Subcutaneous injection of the medical cosmetic product at the surface of the body is like injecting interstitial cells between cells, promoting macrophage proliferation at the injection site, thereby promoting fibroblast proliferation at the site; fibroblasts synthesize and secrete extracellular matrix (EMC) and collagen (type I, type III), elastin and fibronectin; EMC is a matrix composed of macromolecules and minerals, including collagen, enzymes, hyaluronic acid, glycoproteins, proteoglycans, glycosaminoglycans and hydroxyapatite, forming collagen fibers, reticular fibers and elastic fibers, filling the dermis with fibers and matrix components lost due to aging, or filling wounds and appearance defects, forming subcutaneous support for the filling area, changing the appearance of the corresponding area, and producing effects such as narrowing or enlargement. The deep skin injury wound, including acute wound and chronic ulcer wound, such as surgical avulsion, diabetic foot ulcer, pressure sore, etc., can relieve the inflammatory response of the wound, promote the increase of macrophages, and show M2 characterization (p henotype II), promote the growth of capillary endothelial cells and tissue cells (fibroblasts), induce capillary formation, form granulation tissue to fill the wound defect, and finally form a flat tissue foundation for subsequent split thickness skin grafting to cover the wound. The surface surgical site, such as the wound after skin tumor resection and old hypertrophic scar resection, can promote the regeneration of wound granulation tissue by pouring the medical cosmetic product into the wound, and finally transplant the epidermis to complete the repair.

[0027] The aforementioned dextran polyethylene glycol cross-linked microparticle solution is used in the preparation of medical cosmetic products, wherein the medical cosmetic products are used as a base liquid or added to a scaffold material for ADSCs cell skin wound repair.

[0028] The aforementioned dextran polyethylene glycol cross-linked microparticle solution is used in the preparation of medical cosmetic products, wherein the medical cosmetic products can be used for subcutaneous injection, and the injection site is the face, neck or other suitable subcutaneous injection sites.

[0029] In the application of the aforementioned dextran polyethylene glycol cross-linked microparticle solution in the preparation of medical cosmetic products, the face includes the bridge of the nose, forehead, mandible, and temporal region. The collagen, fibroblasts, and fat cells that subsequently proliferate in the injection area form subcutaneous support for the filled area, changing the appearance of the corresponding area.

[0030] In the application of the aforementioned dextran polyethylene glycol cross-linked microparticle solution in the preparation of medical cosmetic products, the other suitable subcutaneous injection sites include the vaginal wall mucosa and the penis body. After injection, it can produce a constriction and enlargement effect.

[0031] In the application of the aforementioned dextran-polyethylene glycol cross-linked microparticle solution in the preparation of medical cosmetic products, the auxiliary material comprises a bioactive agent.

[0032] In the application of the aforementioned dextran polyethylene glycol cross-linked microparticle solution in the preparation of medical cosmetic products, the bioactive agent is selected from stem cells, growth factors, hyaluronic acid, collagen, PLLA, hi-body, amino acids, vitamins, chitosan, mannitol, gelatin or a combination of at least two.

[0033] In the application of the aforementioned dextran polyethylene glycol cross-linked microparticle solution in the preparation of medical cosmetic products, the growth factor is selected from epidermal growth factor, fibroblast growth factor, platelet-derived growth factor, human growth hormone, vascular endothelial growth factor or a combination of at least two of them.

[0034] In the application of the aforementioned dextran polyethylene glycol cross-linked microparticle solution in the preparation of medical cosmetic products, the auxiliary material comprises a cellulose ether substance, and the cellulose ether substance is selected from one or a combination of at least two of methyl cellulose, sodium carboxymethyl cellulose, ethyl cellulose, carboxyethyl cellulose, hydroxypropyl cellulose or hydroxypropyl methyl cellulose.

[0035] In the application of the aforementioned dextran polyethylene glycol cross-linked microparticle solution in the preparation of medical cosmetic products, the auxiliary material comprises an anesthetic, and the anesthetic is selected from one or a combination of at least two of lidocaine, procaine, etidocaine, pramoxine, and quinicaine.

[0036] In the application of the aforementioned dextran polyethylene glycol cross-linked microparticle solution in the preparation of medical cosmetic products, the weight concentration of the dextran polyethylene glycol cross-linked microparticle solution is 1-20wt%.

[0037] Compared with the prior art, the poly(ethylene glycol) cross-linked microparticle solution of the present invention is a bioactive material with high biocompatibility and no irritation. When used subcutaneously, it can promote the proliferation of macrophages in the subcutaneous tissue of the corresponding part, and more than 90% of the proliferating macrophages are characterized by M2. M2 macrophages promote the proliferation of fibroblasts and vascular endothelial cells by secreting TGF-β, IL-10, VEGF-A and growth factors. Fibroblasts synthesize and secrete extracellular matrix (EMC) and collagen (type I, type III); EMC is a matrix composed of macromolecules and minerals, including collagen, enzymes, glycoproteins, proteoglycans, glycosaminoglycans and hydroxyapatite, which provides structural and biochemical support for surrounding cells, provides support for reshaping the tissue structure of the dermis, and eliminates wrinkles and defects in the epidermis. Because it is a fiber filling formed by autologous regeneration of collagen, it has a very natural appearance, is not easy to decompose, and the filling effect can be maintained for up to 24 months. The preparation procedure of the dextran polyethylene glycol cross-linked microparticle solution is simple and convenient, and the product yield is high. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 This is a high-power microscope photo of the dextran polyethylene glycol cross-linked microparticles in the embodiment of the present invention;

[0039] Figure 2 This is the specific immunohistochemical staining image of macrophage Iba in the group injected with normal saline in the experimental example of the present invention;

[0040] Figure 3 This is the specific immunohistochemical staining image of macrophage Iba in the Dex-AE / PEGDA injection group in the experimental example of the present invention;

[0041] Figure 4 Comparison of macrophage-specific staining areas between the NS group and the Dex-AE / PEGDA group;

[0042] Figure 5 Figure 2 shows the immunohistochemical analysis of CCR7 and CD163 in the Dex-AE / PEGDA group;

[0043] Figure 6 Figure 2 shows the immunohistochemical analysis of CCR7 and CD163 in the Dex-AE / PEGDA group;

[0044] Figure 7 Comparison of M1&M2 characterizations in the CCR7 and CD163 immunohistochemical analysis of the Dex-AE / PEGDA group;

[0045] Figure 8 HE staining of skin tissue sections of the NS group;

[0046] Fig. 9HE staining of skin tissue sections in the Dex-AE / PEGDA group. DETAILED DESCRIPTION

[0047] The present invention is further described below in conjunction with the accompanying drawings and embodiments, but they are not intended to limit the present invention.

[0048] Example 1 Polyethylene glycol cross-linked microparticle solution

[0049] It contains two repeating structural units: a first structural unit and a second structural unit. The first structural unit comes from a first monomer, which is polyethylene glycol diacrylate and has structure A. The second structural unit comes from a second monomer, which is a modified high-molecular-weight dextran and has structure D. The dextran polyethylene glycol cross-linked microparticles are formed by ultraviolet cross-linking of the first monomer and the second monomer and have structure C.

[0050]

[0051] Structure D, R1 is H.

[0052]

[0053] The average molecular weight of polyethylene glycol diacrylate, the first monomer of the synthetic structure C, is 3000-5000 Daltons, and the average molecular weight of the modified high molecular weight dextran, the second monomer of the synthetic structure C, is 60,000-62,000 Daltons.

[0054] Example 2 Preparation method of poly(ethylene glycol) cross-linked microparticle solution

[0055] The following steps are included:

[0056] Step A, preparing a solution according to the following concentrations: 90 wt % PBS buffer, 1 wt % of a first monomer polyethylene glycol diacrylate (structure A, average molecular weight 3000-5000 Daltons), and 16 wt % of a second monomer modified high molecular weight dextran (structure D, average molecular weight 60,000-62,000 Daltons) aqueous solution;

[0057] Step B, weighing the photoinitiator I2959 according to 5% of the total weight of the first monomer and the second monomer;

[0058] Step C, mixing the first monomer aqueous solution, the second monomer mixed aqueous solution, the PBS buffer solution, and the photoinitiator I2959, wherein the weight ratio of the first monomer: the second monomer: the PBS is 1:9:90, stirring evenly, filtering twice through a 0.5 μm precision filter pump, and accurately filling into 0.5 mL and 1 mL pre-filled syringes;

[0059] Step D, the filled syringe is placed flat under a 365nm ultraviolet light source, and the cross-linking reaction is carried out at 25°C for 11 hours to obtain a dextran polyethylene glycol cross-linked microparticle solution, which is then sealed in an aluminum foil bag. The dextran polyethylene glycol cross-linked microparticles are strip-shaped fibers, such as Figure 1 As shown, the solution is transparent golden yellow, slightly viscous, and has a pH of 7.3.

[0060] Example 3 Application of dextran polyethylene glycol cross-linked microparticle solution in the preparation of medical cosmetic products

[0061] Subcutaneous support product: Prepare 10wt% dextran polyethylene glycol cross-linked microparticle solution (the dextran polyethylene glycol cross-linked microparticle solution in Example 2 is used as the solute, and the dextran polyethylene glycol cross-linked microparticle solution used in Example 3 is all prepared in Example 2.) Subcutaneously inject it at the wrinkle site, inject 0.1ml at each point, with an interval of about 1cm; after 5-6 weeks, reinforce the injection at the original injection site again according to the original dose; natural subcutaneous filling and wrinkle removal effect appears 1-2 months after the first injection, and can be maintained for 1.5-2 years.

[0062] Deep skin injury wound healing product: prepare 20wt% dextran polyethylene glycol cross-linked microparticle solution, 5mL per tube, inject into the wound after debridement, then cover with other dressings, open and clean the wound after 1 week, replace as before, and regenerate and fill the wound after 4-6 weeks.

[0063] A conventional amount of bioactive agent can be added to the medical beauty product, and the bioactive agent can be selected from stem cells, growth factors, hyaluronic acid, collagen, PLLA, hi body, amino acids, vitamins, chitosan, mannitol, gelatin or a combination of at least two, and the growth factor can be selected from epidermal growth factor, fibroblast growth factor, platelet-derived growth factor, human growth hormone, vascular endothelial growth factor or a combination of at least two. A conventional amount of cellulose ether can be added to the medical beauty product, and the cellulose ether can be selected from one or a combination of at least two of methyl cellulose, sodium carboxymethyl cellulose, ethyl cellulose, carboxyethyl cellulose, hydroxypropyl cellulose or hydroxypropyl methyl cellulose. A conventional amount of anesthetic can be added to the medical beauty product, and the anesthetic is selected from one or a combination of at least two of lidocaine, procaine, etidocaine, pramoxine, and quinicaine.

[0064] Experimental Example 4: Normal saline (NS group) and the dextran polyethylene glycol cross-linked microparticle solution (Dex-AE / PEGDA group) prepared in Example 2 were injected into the left and right sides of the back of mice, respectively (the concentration of the dextran polyethylene glycol cross-linked microparticle solution in Example 2 was 10wt%), the injection dose was 0.2mL, and after 5 days, the tissue sections were immunohistochemically analyzed for Iba, and the brown color was macrophage-specific staining. The specific staining of macrophages Iba in the group injected with normal saline (NS group) was as follows: Figure 2 As shown, the specific staining of Iba in macrophages in the Dex-AE / PEGDA injection group is as follows Figure 3 As shown by Figure 2 and Figure 3 It can be seen that the macrophage count in the Dex-AE / PEGDA group was significantly higher than that in the NS group. The specific staining area of ​​macrophages in the NS group and the Dex-AE / PEGDA group is shown in Table 1; the comparison of the specific staining area of ​​macrophages in the NS group and the Dex-AE / PEGDA group is shown in Figure 4 The immunohistochemical analysis of CCR7 and CD163 in the Dex-AE / PEGDA group showed the M1&M2 characteristics as shown in the figure. Figure 5 and Figure 6 As shown, Figure 5 The red arrow in the middle points to the M1 representation. Figure 6 The white* in the middle is M2, which is represented by Figure 5 and Figure 6 It can be seen that M2 is significantly higher than M1. The comparison of M1 and M2 characteristics in the Dex-AE / PEGDA group is shown in the immunohistochemical analysis of CCR7 and CD163. Figure 7 After Dex-AE / PEGDA was injected into the back of mice, fibroblasts proliferated significantly and the adipocyte layer thickened. The HE staining of the skin tissue sections of the NS group is shown in the figure. Figure 8 As shown, HE staining of skin tissue sections in the Dex-AE / PEGDA group is shown Fig. 9 shown.

[0065] Table 1 Macrophage-specific staining area in NS group and Dex-AE / PEGDA group

[0066]

[0067] The above mouse experiments fully verified that Dex-AE / PEGDA microparticle solution injection can promote macrophage proliferation in the dermis and be characterized by M2. M2-characterized macrophages promote the proliferation of dermal fibroblasts: fibroblasts synthesize and secrete extracellular matrix and collagen, and eventually form collagen fibers, reticular fibers and elastic fibers in the dermis, providing subcutaneous support for the corresponding epidermis, eliminating epidermal wrinkles caused by subcutaneous fiber atrophy due to aging, filling defects caused by trauma or filling appearance defects. Dex-AE / PEGDA is decomposed into glucose and PEG by glucanase in the body. PEG is a drug adjuvant certified by FDA and NMPA. PEG is non-toxic, non-immunogenic, non-antigenic, water-soluble, and can be excreted through the kidneys.

[0068] Of course, the present invention may have many other embodiments. Without departing from the spirit and essence of the present invention, those skilled in the art may make various corresponding changes and modifications based on the present invention, but these corresponding changes and modifications should all fall within the scope of protection of the claims attached to the present invention.

Claims

1. A dextran polyethylene glycol cross-linked microparticle solution, Features: Contains two repeating structural units: a first structural unit and a second structural unit, wherein the first structural unit is derived from a first monomer, and the first monomer is polyethylene glycol diacrylate, and has a structure A; The second structural unit is derived from the second monomer, which is a modified high molecular weight dextran having structure B; Wherein m = 10-100, n = 4-400; R 1 Selected from -OCNHCH 2 CH=CH 2 、-CH 2 CH 2 NH 2 or H; R 2 Selected from -OCNHCH 2 CH=CH 2 、-CH 2 CH 2 NH 2 or H; R 3 Selected from -OCNHCH 2 CH=CH 2 、-CH 2 CH 2 NH 2 or H; The dextran polyethylene glycol cross-linked microparticle solution is formed by ultraviolet cross-linking of a first monomer and a second monomer.

2. The dextran polyethylene glycol cross-linked microparticle solution according to claim 1, Features: With structure C, The average molecular weight of structure A is 200-20,000 Daltons, and the average molecular weight of structure B is 20,000-200,000 Daltons.

3. The dextran polyethylene glycol cross-linked microparticle solution according to claim 1, Features: The particle length of the dextran polyethylene glycol cross-linked microparticles is 10-40 μm.

4. A method for preparing the dextran polyethylene glycol cross-linked microparticle solution according to any one of claims 1 to 3, Features: A photoinitiator and pharmaceutical grade purified water are added to the first monomer and the second monomer, and the mixture is subjected to ultraviolet cross-linking to obtain a dextran polyethylene glycol cross-linked microparticle solution.

5. The method for preparing the dextran polyethylene glycol cross-linked microparticle solution according to claim 4, Features: The following steps are included: Step A, preparing a solution according to the following concentrations: 80-90 wt % of PBS buffer, 1-4 wt % of a first monomer polyethylene glycol diacrylate aqueous solution, and 8-18 wt % of a second monomer modified high molecular weight dextran aqueous solution; Step B, weighing the photoinitiator I2959 at 3-8 wt% of the total weight of the first monomer and the second monomer; Step C, mixing the first monomer aqueous solution, the second monomer aqueous solution, the PBS buffer solution, and the photoinitiator I2959, wherein the weight ratio of the first monomer: the second monomer: PBS is (1-4): (8-18): (80-90), stirring evenly, filtering twice through a 0.5 μm precision filter pump, and injecting into a syringe; Step D, placing the filled syringe flat under a 365nm ultraviolet light source, and performing cross-linking reaction at 20-25°C for 10-12h to obtain a dextran polyethylene glycol cross-linked microparticle solution.

6. Use of the dextran polyethylene glycol cross-linked microparticle solution according to any one of claims 1 to 5 in the preparation of medical cosmetic products.

7. Use of the dextran polyethylene glycol cross-linked microparticle solution according to claim 6 in the preparation of medical cosmetic products, Features: The dextran polyethylene glycol cross-linked microparticle solution is used as the main material, and one or more acceptable auxiliary materials are added to prepare a medical beauty product.

8. Use of the dextran polyethylene glycol cross-linked microparticle solution according to claim 7 in the preparation of medical cosmetic products, Features: The medical cosmetic product is a product that forms subcutaneous support, promotes the healing of deep skin wounds, or repairs surface surgical sites.

9. Use of the dextran polyethylene glycol cross-linked microparticle solution according to claim 8 in the preparation of medical cosmetic products, Features: The medical cosmetic product is used as a base liquid or added to a scaffold material for repairing skin wounds with ADSCs cells.

10. Use of the dextran polyethylene glycol cross-linked microparticle solution according to claim 8 in the preparation of medical cosmetic products, Features: The medical cosmetic product can be used for subcutaneous injection, and the injection site is the face, neck or other suitable subcutaneous injection sites.

11. Use of the dextran polyethylene glycol cross-linked microparticle solution according to claim 7 in the preparation of medical cosmetic products, Features: The excipient comprises a bioactive agent.

12. Use of the dextran polyethylene glycol cross-linked microparticle solution according to claim 11 in the preparation of medical cosmetic products, Features: The bioactive agent is selected from stem cells, growth factors, hyaluronic acid, collagen, PLLA, hi body, amino acids, vitamins, chitosan, mannitol, gelatin or a combination of at least two thereof.

13. Use of the dextran polyethylene glycol cross-linked microparticle solution according to claim 12 in the preparation of medical cosmetic products, Features: The growth factor is selected from epidermal growth factor, fibroblast growth factor, platelet-derived growth factor, human growth hormone, vascular endothelial growth factor or a combination of at least two thereof.

14. Use of the dextran polyethylene glycol cross-linked microparticle solution according to claim 11 in the preparation of medical cosmetic products, Features: The auxiliary material comprises cellulose ether substances, and the cellulose ether substances are selected from one or a combination of at least two of methyl cellulose, sodium carboxymethyl cellulose, ethyl cellulose, carboxyethyl cellulose, hydroxypropyl cellulose or hydroxypropyl methyl cellulose.

15. Use of the dextran polyethylene glycol cross-linked microparticle solution according to claim 14 in the preparation of medical cosmetic products, Features: The auxiliary material comprises an anesthetic, and the anesthetic is selected from one or a combination of at least two of lidocaine, procaine, etidocaine, pramoxine, and quinicaine.

16. Use of the dextran polyethylene glycol cross-linked microparticle solution according to any one of claims 7 to 15 in the preparation of medical cosmetic products, Features: The weight concentration of the dextran polyethylene glycol cross-linked microparticle solution is 1-20wt%.

Images